Clinical Study of Ro200-5450po for Primary Osteoporosis

Phase III Clinical Study of Ro200-5450po (Ibandronic acid) for Primary Osteoporosis

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221937

Enrollment

396

Registered

2012-10-11

Start date

2012-10-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Osteoporosis

Interventions

investigational material(s) Generic name etc : Ro200-5450po INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Primary osteoporosis

Exclusion criteria

Exclusion criteria: Secondary osteoporosis

Design outcomes

Primary

Measure	Time frame
Lumbar spine BMD DXA scan	—

Secondary

Measure	Time frame
-BMD of proximal femur -Biochemical markers of bone turnover -Incidence of fractures DXA scan, Laboratory tests, X-ray	—

Contacts

Public Contact; ;

Chugai Pharmaceutical Co., Ltd.;Taisho Pharmaceutical Co., Ltd.

;;

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026